Growing evidence demonstrates that cancer patients treated with VSP inhibitors, including direct VEGF inhibitors such as anti-VEGF antibodies or decoy receptors, and small molecule VEGF tyrosine kinase inhibitors (TKIs), are at increased risk of developing cardiovascular disease (CVD). This evidence concerns the gene VEGFA and cancer.